Leerink Partnrs Analysts Raise Earnings Estimates for AbbVie

AbbVie Inc. (NYSE:ABBV) – Equities research analysts at Leerink Partnrs upped their FY2026 earnings estimates for shares of AbbVie in a research note issued to investors on Friday, November 22nd. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn $13.69 per share for the year, up from their previous forecast of $13.67. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $10.95 per share. Leerink Partnrs also issued estimates for AbbVie’s FY2027 earnings at $15.36 EPS and FY2028 earnings at $16.79 EPS.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.92 by $0.08. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The business had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.28 billion. During the same period in the previous year, the business earned $2.95 earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on ABBV. Piper Sandler raised their price objective on AbbVie from $196.00 to $209.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. William Blair raised shares of AbbVie to a “strong-buy” rating in a research note on Friday, August 30th. Bank of America lifted their price objective on AbbVie from $185.00 to $195.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price target on shares of AbbVie in a research report on Monday, August 5th. Finally, Argus raised AbbVie from a “hold” rating to a “buy” rating in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $203.50.

AbbVie Stock Up 0.1 %

ABBV opened at $177.06 on Monday. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The business’s fifty day simple moving average is $189.09 and its 200 day simple moving average is $181.44. AbbVie has a 52 week low of $137.65 and a 52 week high of $207.32. The stock has a market cap of $312.89 billion, a PE ratio of 61.48, a P/E/G ratio of 2.16 and a beta of 0.63.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a dividend yield of 3.70%. The ex-dividend date is Wednesday, January 15th. This is a boost from AbbVie’s previous quarterly dividend of $1.55. AbbVie’s dividend payout ratio (DPR) is currently 227.78%.

Hedge Funds Weigh In On AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC grew its position in shares of AbbVie by 0.7% during the third quarter. Tidal Investments LLC now owns 113,375 shares of the company’s stock worth $22,389,000 after purchasing an additional 780 shares in the last quarter. Destination Wealth Management grew its holdings in AbbVie by 68.1% during the 3rd quarter. Destination Wealth Management now owns 3,369 shares of the company’s stock valued at $665,000 after buying an additional 1,365 shares in the last quarter. Wilmington Savings Fund Society FSB grew its holdings in shares of AbbVie by 157.0% in the third quarter. Wilmington Savings Fund Society FSB now owns 82,223 shares of the company’s stock valued at $16,237,000 after purchasing an additional 50,231 shares in the last quarter. Arvest Bank Trust Division purchased a new position in shares of AbbVie in the 3rd quarter worth $18,015,000. Finally, Sanctuary Advisors LLC lifted its holdings in shares of AbbVie by 23.7% in the 3rd quarter. Sanctuary Advisors LLC now owns 528,802 shares of the company’s stock valued at $104,428,000 after acquiring an additional 101,455 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.